ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,307.01
      -0.27%
      US Tech 100
      18,307.16
      0.41%
      Dow Jones
      39,671.04
      -0.51%
      Brent Oil
      81.145
      -0.47%
      Bitcoin
      69,353.36
      0.36%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. CervoMed Inc (CRVO)

      7. CervoMed Inc (CRVO) News

      CRVO

      CervoMed (CRVO)

      CervoMed Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CRVO
      DateTimeSourceHeadlineSymbolCompany
      05/20/20248:00AMGlobeNewswire Inc.CervoMed to Appoint William Elder as Chief Financial OfficerNASDAQ:CRVOCervoMed Inc
      05/15/20248:00AMGlobeNewswire Inc.CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:CRVOCervoMed Inc
      04/01/20248:00AMGlobeNewswire Inc.CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdatesNASDAQ:CRVOCervoMed Inc
      03/28/20248:30AMGlobeNewswire Inc.CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare InvestorsNASDAQ:CRVOCervoMed Inc
      03/05/20248:00AMGlobeNewswire Inc.CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024NASDAQ:CRVOCervoMed Inc
      02/21/20248:00AMGlobeNewswire Inc.CervoMed to Participate in the BIO CEO and Investor ConferenceNASDAQ:CRVOCervoMed Inc
      02/12/20248:00AMGlobeNewswire Inc.CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy BodiesNASDAQ:CRVOCervoMed Inc
      02/07/20248:30AMGlobeNewswire Inc.CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the BoardNASDAQ:CRVOCervoMed Inc
      02/05/20248:00AMGlobeNewswire Inc.CervoMed to Participate in the Emerging Growth Conference 67NASDAQ:CRVOCervoMed Inc
      01/05/20248:00AMGlobeNewswire Inc.CervoMed to Participate in the Emerging Growth Conference 66NASDAQ:CRVOCervoMed Inc
      11/13/20237:00AMPR Newswire (US)CervoMed Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:CRVOCervoMed Inc
      10/25/20232:50PMPR Newswire (US)CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy BodiesNASDAQ:CRVOCervoMed Inc
      10/24/20237:00AMPR Newswire (US)CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major DementiasNASDAQ:CRVOCervoMed Inc
      10/18/20237:00AMPR Newswire (US)CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy BodiesNASDAQ:CRVOCervoMed Inc
      10/05/20237:00AMPR Newswire (US)CervoMed to Present at the 2023 Roth Healthcare Opportunities ConferenceNASDAQ:CRVOCervoMed Inc
      09/05/20237:00AMPR Newswire (US)CervoMed to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:CRVOCervoMed Inc
       Showing the most relevant articles for your search:NASDAQ:CRVO